Kornimate/medical-research-clean huggingface dataset:
persistency study after hib-crm (cross-reacting material)197 or hib-tt (tetanus toxoid) vaccines in chinese children

Conditions: Meningitis, Epiglottitis, Pneumonia, Arthritis Caused by Haemophilus Influenzae Type b

Summary: evaluate the persistency of immune response against haemophilus influenzae type b by assessing anti-prp antibody levels in children vaccinated with either hib-crm197 or hib-tt booster vaccine approximately 4 years before.


Eligibility criteria:
inclusion criteria: 1. children previously enrolled in v37_07e1 study and who received the appropriate vaccination. 2. children whose parent(s) or legal guardian(s) had given written consent after the nature of the study was explained according to local regulatory requirements. exclusion criteria: 1. any confirmed or suspected current immunosuppressive or immunodeficient condition since the end of v37_07e1 study, based on medical history and physical examination (no laboratory testing required). 2. treatment with corticosteroids or other immunosuppressive/immunostimulant drugs as defined below: i) chronic use of oral and parenteral immunosuppressants (\>= 15 days of use) or other immune-modifying drugs within 60 days prior to the blood sampling (short term usage of topical, inhaled and/or intranasal corticosteroids were allowed) ii) receipt of immunostimulants within 60 days prior to visit 1 3. administration of immunoglobulins and/or any blood products up to 3 months before enrollment. 4. use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the blood sampling. 5. any condition, which, in the opinion of the investigator, might be a contraindication to the execution of the blood draw.

Keywords: haemophilus influenzae type b persistency children crm197 anti-prp antibody
chemotherapy and dli for prevention of second relapse in patients with relapsed acute leukemia after allotransplant

Conditions: Donor Lymphocyte Infusion; Allogeneic Hematopoietic Stem Cell Transplantation; Acute Leukemia; Minimal Residual Disease; Graft-versus-host Disease; Relapse

Summary: patients with acute leukemia relapsing after allotransplant and who respond to anti-leukaemia interventions are at high-risk of a second relapse. previous studies from investigators reported an association between a positive minimal residual disease (mrd)-test after transplant and an increased risk of subsequent relapse. also, patients developing chronic graft-versus-host disease (gvhd) after receiving dli (donor lymphocyte infusion)for leukemia relapse after a first allotransplant have a lower likelihood of a second relapse compared with similar patients not developing chronic gvhd. and, our previous study also reported patients with chronic gvhd after dli was associated with a greater frequency of a negative mrd-test and lower likelihood of subsequent relapse compared with similar persons not developing chronic gvhd. based on these data the investigators designed a randomized control study to determine whether giving additional consolidation chemotherapy and dli might decrease likelihood of second relapse in persons without chronic gvhd or with a positive mrd-test after initial post-relapse therapy with induction chemotherapy and dli.


Eligibility criteria:
inclusion criteria: * (1) acute leukemia in first complete or second complete remission; * (2) relapse after an allotransplant; * (3) had full or partial donor chimerism; * (4) received re-induction chemotherapy and dli and achieved a negative mrd-test. exclusion criteria: * (1) active gvhd * (2) active infection * (3) organ dysfunction
pilot trial to assess 68ga bombesin pet/ct (neob) imaging for staging of breast cancer

Conditions: Breast Cancer

Summary: this phase iib pilot study will enrol 20 patients (women) presenting with metastatic breast cancer (er/pr + her2- on histology) who require imaging for staging or re-staging of their disease.

there is little published literature evaluating the usefulness of ga bombesin-pet imaging in comparison to currently accepted imaging modalities for detecting progressive metastatic breast cancer. this study aims to produce preliminary research to evaluate its clinical value in breast cancer, given the promising previously published cell line and mouse work in er/pr+ her2- tumours. it further aims to ascertain the theranostic potential of the neob peptide in the er/pr + her 2- population, particularly assessing the level of heterogeneity at sites of active malignancy compared to fdg pet. this study will add pet ct imaging using a tracer agent (neob) that directly targets the breast cancer cell. the ability of this new pet ct scan to detect sites of metastatic disease will be compared to standard procedures which include diagnostic ct, bone scan and 18f-fdg pet. all patients will undergo a single time point imaging at day 0 with pet ct to be conducted 120 (+/- 30) minutes after intravenous administration with 68ga neob (3.0mbq/kg).

Eligibility criteria:
inclusion criteria: * female patients aged 18 or above * ability to provide informed consent documentation indicating that they understand the purpose of and procedures required for the study, and are willing to participate in the study * estrogen/progesterone receptor +ve her2 negative disease confirmed on prior biopsy (primary or metastatic site). * metastatic breast cancer being staged or re-staged prior to treatment of metastatic disease (including those presenting with up-front metastatic disease with primary breast cancer in-situ and those who have progressed on a line of treatment for metastatic breast cancer that are suitable for another line of treatment) * metastatic breast cancer being staged or restaged prior to change in treatment with standard imaging within 3 weeks of enrolment (ct cap, bone scan, fdg pet ct) exclusion criteria: * pregnancy or lactation (patients should use highly effective methods of contraception during and for 12h after administration) * significant inter-current acute illness as per investigator discretion that prevent undertaking study procedures * history of current active malignancy as per investigator discretion other than breast cancer. * known or expected hypersensitivity to 68ga neob
the effect of exercise on anxiety and cognition in students at university

Conditions: Exercise; Anxiety; Depression; Cognition

Summary: rationale: exercise may improve the mood and cognition in young people. purpose: it has been well-known that physical exercise can generally benefit the mental health. however, most evidences that physical exercise improves psychiatric symptoms come from retrospective or cross-sectional studies. moreover, the studies on the effect of physical exercise in the young adults' mental health were limited. this randomized-controlled trial aims to determinate the effects of a chronic and aerobic exercise on the mood and cognition of young people.

objectives: the anxiety and depression symptoms in young people are worth paying attention to, in china and worldwide. meanwhile, cognitive function is very important for young people's learning and work. this project aims to evaluate the effectiveness of the moderate aerobic exercise to alleviate anxiety and depression in young people. design \& methods: undergraduate and graduate students aged 18-35 years will be randomly and evenly assigned to exercise and control groups. subjects assigned to exercise group will receive an running exercise intervention more than 30 minutes and 3 times per week for 8 weeks. the control group will be advised not to engage in physical activities. outcome measures include the score of the self-rating anxiety scale (sas), self-rating depression scale (sds), the response time of schulte grid test, and the response time of stroop colour-word test at baseline and post-intervention in two groups. in addition, these assessments will be followed up at week 20 (3 months after the end of intervention).

Eligibility criteria:
inclusion criteria: * undergraduate and graduate students aged 18 to 35 years. exclusion criteria: * heart disease, hypertension, cardiovascular and respiratory system diseases such as asthma and are unable to tolerate the frequency and strength of exercise requirements. * any neurological or psychiatric disorders. * physical disabilities. * severe dysmenorrhea when they couldn't exercise more than 5 days before or after menstruation. * color blindness.
role of low inferior mesenteric artery ligation during laparoscopic surgery for rectosigmoid cancer

Conditions: Rectosigmoid Adenocarcinoma

Summary: during sigmoid or rectal cancer surgery, dissection of lymphnodes at the origin of inferior mesenteric artery is mandatory. nevertheless, ligation of the origin of ima should compromise blood supply to left colon and affect anastomosis. the aim of this retrospective evaluation is to compare high and low ima ligation with preservation of lca, with or without skeletonization of the origin of ima in laparoscopic colorectal resection.


Eligibility criteria:
inclusion criteria: * stage i-iii carcinoma exclusion criteria: * stage iv * urgent resection * conversion to open surgery
method of assessment of driving ability in patients suffering from wakefulness pathologies.

Conditions: Cirrhosis

Summary: the project will improve scientific knowledge regarding a recent law applying potentially to every french driver. it will give for the first time an indication on the impact of alerting treatments on driving risks. it will reinforce the links between different research environments (sleep physiopathology, clinical research, cognitive neurosciences, drivers supervision, virtual reality, pharmacology) among the "réseau eveil sommeil attention et transports" (resat) network.

excessive daytime sleepiness is responsible of 20% of traffic accidents and 2/3 of truck accidents on french freeways. since the publication of a new law (2005 december 28th - official journal) regulating fitness to drive, the maintenance of wakefulness test (mwt) is now mandatory to evaluate driving skills of patients suffering of excessive daytime sleepiness. the mwt has shown a good predictability of driving handicap on simulators in patients suffering from obstructive sleep apnea syndrome. nevertheless no study has proven yet the predictability of the mwt regarding real and simulated driving in patients suffering from hepatic encephalopathy. furthermore, even if therapeutic drugs significantly improve mwt scores there is no data available concerning the impact of these drugs on fitness to drive. lactulose, a treatment of hepatic encephalopathy, has not been tested as a counter measure to driving impairment. this lack of knowledge is a major handicap to evaluate driving skills of treated patients suffering from excessive daytime sleepiness. the main objective of our project is to test the predictive value of the mwt on real and simulated driving performances in untreated and treated sleepy patients suffering from hepatic encephalopathy.

Eligibility criteria:
inclusion criteria: * cirrhosis proved by histologic or clinico-biologics criteria, whatever its severity, its stability defined by a child stable score (variation \< 2 points for the last month) without any other disease which could be responsible of excessive daytime sleepiness * driver's licence since at least 2 years * driving more than 2000 km/year * registered to french national health and pensions organization * having given their written light agreement in order to participate in the study. exclusion criteria: * night workers * neurologic disease * recent strong complication (\< 30 days) * recent antibiotics or lactulose intake * substance abusers (alcohol) * hepatoma more than 5 cm * disorder associated which engaged life prognostic in a short time * glycemia fasted \> 8 mmol/l * haemoglobin \< 10g/l * neurologic or psychiatric disorders associated which affect superiors functions, * hepatic encephalopathy stage 3 or 4 * having participated in a clinical study during the last 6 months * drugs abusers * unable to drive.

Keywords: sleep cirrhosis encephalopathy simulated driving sleep disorders
guided pterygoid implant

Conditions: Atrophy of the Posterior Maxilla

Summary: introduction \& background alveolar ridge resorption after tooth extraction leads to significant bone loss, complicating prosthetic rehabilitation. traditional bone grafting methods, though effective, involve long healing times and risks. pterygoid implants offer a graft-free alternative by engaging dense bone structures like the pterygoid process. however, their placement is technically challenging due to limited visibility and proximity to critical structures. computer-guided surgery may improve accuracy and reduce complications compared to freehand techniques. research question does computer-guided surgery enhance the accuracy of pterygoid implant placement in atrophic maxillae compared to freehand techniques? aim to compare the accuracy of computer-generated 3d surgical guides versus freehand placement of pterygoid implants. hypothesis * h0: no difference in accuracy between techniques. * hₐ: there is difference between two techniques study design a prospective randomized controlled trial (1:1 allocation) with 12 implants (6 per group(. patient selection inclusion criteria: severe posterior maxillary atrophy (cawood \& howell v-vi), residual bone height \<4mm, age 21-75. exclusion criteria: contraindications for surgery, uncontrolled systemic diseases, or acute sinus infections. methods * group a: implants placed using cbct-based 3d surgical guides. * group b: freehand placement based on anatomical landmarks. * primary outcome: implant position accuracy (postoperative cbct vs. virtual plan(. * secondary outcomes: surgical time, complications, and stability. surgical procedure * osteotomy: angled drilling (45-60°) into the pterygoid process. * implant placement: torque ≥30 ncm for primary stability. * postoperative care: antibiotics, analgesics, and follow-up cbct at one week. statistical analysis data analyzed using spss, with g\*power determining sample size (85% power, α = 0.05(. ethical considerations approved by institutional review boards, with informed consent and confidentiality maintained.


Eligibility criteria:
inclusion criteria: 1. patients with severe posterior maxillary atrophy (class v-vi cawood \& howell classification) requiring pterygoid implant placement. 2. patients with severe alveolar bone atrophy in posterior maxilla (residual alveolar bone height \<4mm in posterior maxilla precluding conventional implant placement). 3. adequate interarch space ≥7mm for prosthetic rehabilitation. 4. presence of pneumatized maxillary sinus with insufficient bone for sinus augmentation. 5. patients aged 21-75 years with completed craniofacial growth. exclusion criteria: 1. patients with systemic conditions contra-indicating general anesthesia. 2. patients with conditions contraindicating implant placement (e.g.: radiation to the head and neck, intra-venous bisphosphonates, uncontrolled diabetes mellitus). 3. patients with acute maxillary sinus infection or maxillary sinus cyst. 4. restricted mouth opening (less than 3cm inter-arch distance anteriorly).

Keywords: guided surgery pterygoid implant atrophic maxilla
transdermal nicotine and melatonin patches for postoperative pain relief

Conditions: Postoperative Pain Relief

Summary: sixty female non-smoker patients, aged 18-50 years and asa i and ii undergoing elective laparoscopic cholecystectomy under general anesthesia were included in this randomized controlled double-blind study. patients were randomly divided into 3 groups 20 each, c group patients received transdermal placebo patch, tdn group (15 mg/16 h) and tdm group (7 mg/8h). assessment of postoperative pain, sedation, hemodynamic variables such as hr and map, postoperative monitoring of arterial spo2 and side effects (e.g. nausea, vomiting, pruritis, respiratory depression and hemodynamic instability) were done 30 minutes, 1, 2, 6 and 12 hours postoperatively. postoperative patient's and surgeons' satisfaction, intraoperative bleeding and plasma cortisol (µg / dl) 2 hours postoperatively were also assessed.


Eligibility criteria:
inclusion criteria: * 60 female patients. * non-smoker patients. * aged between 18 and 50 years old. * asa physical status i and ii. * 70-90 kg body weight and height 160-180 cm. * undergoing elective laparoscopic cholecystectomy under general anesthesia. exclusion criteria: * patients with impaired kidney or liver functions. * history of cardiac or central nervous system disease. * history of smoking. * history of drug or alcohol abuse. * history of chronic pain or daily intake of analgesics. * uncontrolled medical disease (diabetes mellitus and hypertension). * history of intake of non-steroidal anti-inflammatory drugs or opioids within 24 h before surgery. * allergy to the used medications. * coagulation defect. * local infection at the site of application of transdermal patch. * patient's refusal. * duration of surgery more than 120 minutes.

Keywords: transdermal nicotine transdermal melatonin postoperative pain laparoscopic cholecystectomy
predictive value of combining accuimr and accuffr in patients with stemi

Conditions: Acute ST Segment Elevation Myocardial Infarction; Prognosis

Summary: patients with acute myocardial infarction were enrolled retrospectively. the fractional flow reserve (accuffr) and microcirculatory resistance index (accuimr) based on coronary angiography were analyzed, and the relationship between ffr and imr and the prognosis of patients with acute myocardial infarction was analyzed

we retrospectively enrolled stemi patients who underwent pci in peking university third hospital. the fractional flow reserve (accuffr) and microcirculatory resistance index (accuimr) based on coronary angiography were obtained by analyzing the coronary angiography images. the prognosis of patients was obtained by searching inpatient and outpatient systems and telephone follow-up. the relationship between accuffr, accuimr and prognosis was statistically analyzed

Eligibility criteria:
inclusion criteria: * age of \>18 years; * onset-to-treatment time of ≤12 h, meeting the diagnostic criteria for stemi; * underwent primary pci within 12 h of symptom onset and achieved successful pci in the culprit vessel; * availability of complete clinical data exclusion criteria: * severe tortuosity and overlap of the target vessel; * poor-quality coronary angiography images; * missing two coronary angiography images \>25° apart
irinotecan in treating patients with metastatic or inoperable thyroid cancer

Conditions: Head and Neck Cancer

Summary: rationale: drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. purpose: this phase ii trial is studying how well irinotecan works in treating patients with metastatic or inoperable thyroid cancer.

objectives: primary * determine the response rate in patients with metastatic or inoperable locoregional medullary thyroid cancer treated with irinotecan. secondary * determine the safety and tolerability of this drug in these patients. outline: patients receive irinotecan iv on days 1 and 8. treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. response is assessed after completion of 4 courses. patients achieving complete response (cr) or partial response (pr) receive 2 additional courses beyond cr or pr. patients who have stable disease receive up to 12 total courses. projected accrual: a total of 33 patients will be accrued for this study.

Eligibility criteria:
inclusion * histologically confirmed medullary thyroid cancer * metastatic or inoperable locoregional disease * measurable disease by ct scan * 18 years and over * ecog ps 0-1 adequate lab functions including: * granulocyte count \> 1,000/mm\^3 * platelet count \> 100,000/mm\^3 * bilirubin \< 1.5 mg/dl * alt and ast \< 2.5 times upper limit of normal * no unstable or uncompensated hepatic disease * creatinine clearance \> 60 ml/min * no unstable or uncompensated renal disease * negative pregnancy test * more than 3 months since prior biologic therapy * more than 3 months since prior chemotherapy * no prior radiotherapy to \> 25% of bone marrow * more than 3 months since prior radiotherapy * recovered from prior oncologic or other major surgery * more than 30 days since prior non-approved or investigational drugs exclusion: * patients with elevated calcitonin levels as the only measurement of disease are not eligible * unstable or uncompensated cardiovascular disease * unstable or uncompensated respiratory disease * pregnant or nursing * diarrhea ≥ grade 2 (antidiarrheals allowed) * other severe or uncontrolled systemic disease * other malignancy within the past 5 years except squamous cell or basal cell skin cancer or cervical cancer * illness that would preclude study participation * significant clinical disorder or laboratory finding that would preclude study participation

Keywords: thyroid gland medullary carcinoma recurrent thyroid cancer
pentoxifylline as anti-inflammatory in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: rheumatoid arthritis (ra) is a long-term inflammatory condition that leads to gradual damage of joints lined by synovial membranes, along with various potential effects outside of the joints. while ra can affect any joint, it typically involves the metacarpophalangeal, proximal interphalangeal, and metatarsophalangeal joints, as well as the wrists and knees. symptoms related to the joints and surrounding tissues include swelling, tenderness upon touch, morning stiffness, and significant difficulty moving the affected joints


Eligibility criteria:
inclusion criteria: * patients with active rheumatoid arthritis (not in remission) according to american college of rheumatology/european league against rheumatism (acr/eular) \[9\] i.e., 28 joints disease activity score (das 28) \>2.6. * patients receiving the conventional dmards. * both sexes. * age range between 18and 70 years old exclusion criteria: * patients with retinal or cerebral hemorrhage. * patients with renal and hepatic dysfunction. * patients with hypersensitivity to study medications. * pregnant and lactating females. * patients receiving biological or synthetic dmards